RecruitingPhase 2NCT05924100

Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD

Studying Myelodysplastic neoplasm with low blasts

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Associazione Qol-one
Intervention
Luspatercept Injection [Reblozyl](drug)
Enrollment
22 enrolled
Eligibility
18 years · All sexes
Timeline
20222029

Study locations (23)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05924100 on ClinicalTrials.gov

Other trials for Myelodysplastic neoplasm with low blasts

Additional recruiting or active studies for the same condition.

See all trials for Myelodysplastic neoplasm with low blasts

← Back to all trials